clinical trial · NCT07512596
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase2·not yet recruiting·n = 48
Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaTQD3524Meropenem for injectionColistimethate Sodium for Injection
brief summary
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
started
Apr 1, 2026
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Apr 6, 2026
official title
Randomized, Double-blind, Parallel-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Polymyxin E2 Mesylate Intravenous Infusion Combined With Nebulized Inhalation in the Treatment of Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Gram-negative Bacteria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol